Medpace

Medpace is a global contract research organization, or CRO, headquartered in Cincinnati, Ohio. The company supports pharmaceutical, biotechnology, and medical-device sponsors throughout the clinical-development process, operating as a full-service provider rather than limiting its work to a single trial function. Its capabilities cover Phase I through Phase IV programs and include development-plan and protocol design, clinical project management, regulatory affairs, clinical monitoring, data management, statistical analysis, and post-marketing support. The business was founded in Cincinnati in 1992 by August Troendle under the name Medical Research Services. Troendle had previously worked in regulatory and pharmaceutical environments, including as a reviewer at the United States Food and Drug Administration, where he focused on lipid-lowering therapies for high cholesterol. This background helped shape Medpace's emphasis on medically led development programs and therapeutic expertise. Early studies conducted by Medpace and its laboratory operations included work on statin therapies for hypercholesterolemia. Company physicians also developed expertise in metabolic diseases, including diabetes and obesity. Medpace expanded beyond its original domestic base through a series of acquisitions between 2007 and 2012. These transactions added contract-research, pharmaceutical-consulting, and medical-device capabilities in the Czech Republic, Switzerland, Germany, the Netherlands, and the United States. The acquisitions supported the company's international operating model and broadened its ability to manage multinational studies. Its service portfolio includes global central laboratory services, imaging core laboratory work, and bioanalytical laboratory services. Medpace also operates a Phase I unit at its Cincinnati headquarters and clinical research campus. The company's principal operating regions are North America, Europe, and Asia, with additional clinical and operational coverage in Latin America. Its customer base consists primarily of sponsors developing medicines, biologics, and medical devices. Medpace's Cincinnati campus was developed on a former industrial brownfield site in the Madisonville neighborhood. Completed in 2012, the campus consolidated offices, laboratories, and clinical facilities and was designed as a LEED-certified project. In 2022, the company announced a planned $150 million expansion of its Cincinnati headquarters, with an estimated 1,500 additional jobs associated with the investment. The ownership structure changed before the company became publicly traded. CCMP Capital acquired an 80 percent interest in 2011, and Cinven acquired that stake in 2014. Medpace later entered the public market through an initial public offering in 2016, when it began trading as a public company. The company continues to operate under the Medpace brand as an international, medically focused CRO.

Medpace was established in Cincinnati in 1992 by August Troendle as Medical Research Services. Troendle entered the CRO field after experience in both pharmaceutical and regulatory work. Earlier in his career, he served as a reviewer at the United States Food and Drug Administration, concentrating on the development of lipid-lowering treatments for hypercholesterolemia. That regulatory and therapeutic background influenced Medpace's development as a medically oriented clinical-research provider. During its early years, Medpace conducted clinical studies with a team of physicians and developed related laboratory capabilities through Medpace Reference Laboratories. Work associated with the company included studies of statin therapies for high cholesterol. Medpace physicians also built expertise in metabolic conditions, particularly diabetes and obesity. The company later broadened its scope from individual studies to integrated development programs spanning clinical operations, regulatory work, laboratory testing, and post-marketing activities. International expansion accelerated between 2007 and 2012. Medpace acquired the Czech contract research organization Monax in 2007 and Switzerland-based PharmaBrains AG in 2009. In 2010, it acquired Symbios, a Minneapolis medical-device consultancy, and Medical Consulting Dr. Schlichtiger GmbH in Germany. The 2012 acquisition of MediTech BV, a Netherlands-based medical-device consultancy, further expanded its European presence and device-development expertise. The company also invested in its Cincinnati infrastructure. A new headquarters and research campus was completed in 2012 in Madisonville on a former NuTone industrial brownfield site. The campus was designed as a LEED-certified development and brought together offices, laboratories, and clinical facilities, including a Phase I unit. This physical concentration supported Medpace's full-service operating model and its laboratory and early-stage clinical capabilities. Medpace's ownership changed during the following decade. In 2011, private-equity firm CCMP Capital acquired an 80 percent interest in the business for a reported $285 million. CCMP later sold that stake to Cinven in February 2014 in a transaction reported at approximately $900 million. Medpace subsequently entered the public markets through an initial public offering in 2016, offering 8,050,000 common shares and becoming a publicly traded company. As an operating company, Medpace manages Phase I through Phase IV development programs for pharmaceutical, biotechnology, and medical-device sponsors. Its services include trial strategy and protocol design, project management, regulatory affairs, site and patient operations, monitoring, data management, statistical analysis, central laboratory work, imaging, bioanalysis, and post-marketing support. Its principal regions are North America, Europe, and Asia, supplemented by operations and clinical coverage in Latin America. In 2022, Medpace announced a $150 million investment to expand its Cincinnati headquarters. The company estimated that the expansion would add roughly 1,500 jobs. The investment represented a continued commitment to its Cincinnati base while the company maintained a global delivery model. Medpace remains active as a full-service CRO under the Medpace brand.

• 2022

  Headquarters expansion announced

  [1]Medpaceen.wikipedia.org

  Medpace announces a $150 million Cincinnati headquarters expansion expected to support approximately 1,500 new jobs.

• 2016

  Initial public offering

  [1]Medpaceen.wikipedia.org

  Medpace becomes a publicly traded company through an initial public offering.

• 2014

  Cinven acquires CCMP's stake

  [1]Medpaceen.wikipedia.org

  Cinven purchases CCMP Capital's 80 percent interest in the company.

• 2012

  Cincinnati campus completed

  [1]Medpaceen.wikipedia.org

  Medpace completes a new LEED-certified campus in Cincinnati's Madisonville neighborhood and acquires Dutch medical-device consultancy MediTech BV.

• 2011

  CCMP Capital acquires a majority interest

  [1]Medpaceen.wikipedia.org

  CCMP Capital acquires an 80 percent stake in Medpace.

• 2010

  Expansion into medical-device consulting

  [1]Medpaceen.wikipedia.org

  Medpace acquires Symbios in the United States and Medical Consulting Dr. Schlichtiger GmbH in Germany.

• 2009

  Acquisition of PharmaBrains AG

  [1]Medpaceen.wikipedia.org

  The company acquires Switzerland-based PharmaBrains AG.

• 2007

  Acquisition of Monax

  [1]Medpaceen.wikipedia.org

  Medpace acquires the Czech Republic contract research organization Monax as part of its international expansion.

• 1992

  Medpace is founded in Cincinnati

  [1]Medpaceen.wikipedia.org

  August Troendle establishes the company as Medical Research Services, laying the foundation for the Medpace CRO business.

A medically focused, full-service CRO combining clinical operations with laboratory, imaging, bioanalytical, regulatory, and post-marketing capabilities for global development programs.

• Clinical research services

  Full-service clinical development

  Medpace manages clinical development programs from Phase I through Phase IV for pharmaceutical, biotechnology, and medical-device sponsors. The offering can encompass development planning, protocol design, project management, clinical monitoring, regulatory affairs, data management, statistical analysis, and support after market authorization.

• Laboratory services

  Central laboratory services

  The company provides global central laboratory services for clinical trials, supporting standardized sample handling, testing, and laboratory data delivery across geographically distributed studies.

• Imaging services

  Imaging core laboratory services

  Medpace's imaging core laboratory capability supports the centralized review and management of imaging data generated during clinical studies, helping sponsors apply consistent processes across trial sites and regions.

• Bioanalysis

  Bioanalytical laboratory services

  Bioanalytical services support the measurement and interpretation of biological samples in development programs. They complement Medpace's clinical and central-laboratory operations within its integrated CRO model.

• Early-phase clinical research

  Phase I unit

  Medpace operates a Phase I unit at its Cincinnati headquarters and clinical research campus. The facility supports early-stage clinical research alongside the company's broader development, laboratory, and medical capabilities.

• Medical-device consulting and clinical research

  Medical-device development services

  Through its CRO operations and acquired medical-device consulting capabilities, Medpace supports clinical and regulatory work for device sponsors as well as traditional pharmaceutical and biotechnology customers.

• 2022

  Cincinnati headquarters expansionStrategy

  Background

  Medpace planned to expand its main campus while maintaining Cincinnati as its headquarters and clinical-research base.

  Action taken

  The company announced a $150 million capital investment and estimated that the expansion would create approximately 1,500 jobs.

  Aftermath

  The plan represented a substantial continued investment in the Cincinnati campus.

  Planned capital investment. $150 million (2022 announcement)

  Source

• 2016

  Initial public offeringOther

  Background

  After a period of private-equity ownership, Medpace pursued access to public capital markets.

  Action taken

  Medpace completed an initial public offering and sold 8,050,000 common shares.

  Aftermath

  The company became publicly traded.

  Source

• 2014

  Cinven acquisition of majority stakeM&A

  Background

  CCMP Capital put its majority interest in Medpace up for sale.

  Action taken

  Cinven acquired CCMP's 80 percent stake for a reported $900 million.

  Aftermath

  Cinven became the majority financial owner before Medpace's later public offering.

  Transaction value. $900 million (February 2014)

  Source

• 2012

  Acquire MediTech BVM&A

  Background

  Medpace continued building its European medical-device consulting network.

  Action taken

  The company acquired MediTech BV, a medical-device consultancy based in the Netherlands.

  Aftermath

  The acquisition strengthened Medpace's Dutch and broader European device-development presence.

  Source

• 2011

  CCMP Capital investmentM&A

  Background

  Medpace entered a private-equity ownership phase while continuing its expansion.

  Action taken

  CCMP Capital acquired an 80 percent interest in Medpace for a reported $285 million.

  Aftermath

  The transaction placed majority ownership with CCMP Capital until its stake was sold to Cinven in 2014.

  Transaction value. $285 million (2011)

  Source

• 2010

  Add medical-device consulting capabilitiesM&A

  Background

  Medpace sought to broaden its services beyond pharmaceutical clinical research.

  Action taken

  It acquired Symbios in Minneapolis and Medical Consulting Dr. Schlichtiger GmbH in Germany.

  Aftermath

  The transactions expanded the company's medical-device and European consulting capabilities.

  Source

• 2007

  Acquire Monax to expand European CRO coverageM&A

  Background

  Medpace was expanding its international clinical-research footprint.

  Action taken

  The company acquired Monax, a contract research organization based in the Czech Republic.

  Aftermath

  The acquisition added a Central European operating presence.

  Source

1. 1Medpaceen.wikipedia.org